

Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer's Association International Conference[®]

New York, NY, July 8, 2013 – [Oligomerix, Inc.](http://www.oligomerix.com), a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the company will present three posters during the Alzheimer's Association International Conference[®] (AAIC) to be held July 13 - 18, 2013, in Boston, MA at the Boston Convention & Exhibition Center.

The posters will highlight Oligomerix's programs, which include the development of small molecules and antibodies aimed at reducing tau oligomer levels that are thought to be acutely toxic in diseases such as AD and other tauopathies.

Sunday, July 14, 2013:

Title: Detection of soluble oligomeric tau with morphology specific antibody fragments as a potential diagnostic for AD
Authors: Huilai Tian, Eliot Davidowitz, Ph.D., James Moe, Ph.D., Mike Sierks, Ph.D.
Poster: P1-212
Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

Title: Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between AD and non-AD specimens
Authors: Eliot Davidowitz, Ph.D., Patricia Lopez, M.S., James Moe, Ph.D.
Poster: P1-411
Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

Wednesday, July 17, 2013:

Title: Small molecule lead identification for inhibition of tau oligomer formation
Authors: James Moe, Ph.D., James Hendrix, Ph.D., Patricia Lopez, M.S., Robert Kilkuskie, Ph.D., Steve Vroegop, M.S., Eliot Davidowitz, Ph.D.

Poster: P4-423
Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

ABOUT OLIGOMERIX

Oligomerix, Inc. is a biopharmaceutical company focused on discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. The Company is seeking strategic partners to help accelerate these exciting programs. For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:

[Oligomerix, Inc.](#)

Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

[Tiberend Strategic Advisors, Inc.](#)

Andrew Mielach
212-375-2694
amielach@tiberend.com